Page last updated: 2024-12-10
pentachloropseudilin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pentachloropseudilin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3053233 |
| CHEMBL ID | 1738815 |
| SCHEMBL ID | 12666317 |
| MeSH ID | M0475652 |
Synonyms (20)
| Synonym |
|---|
| a15104 y |
| 2,4-dichloro-6-(3,4,5-trichloro-2-pyrrolyl)phenol |
| brn 1484123 |
| phenol, 2,4-dichloro-6-(3,4,5-trichloro-2-pyrrolyl)- |
| 2,4-dichloro-6-(3,4,5-trichloro-1h-pyrrol-2-yl)phenol |
| pentachloropseudilin |
| bdbm50345503 |
| chembl1738815 , |
| 2,4-dichloro-6-(3,4,5-trichloro-1h-pyrrol-2yl)phenol |
| IA2 , |
| 5-21-03-00330 (beilstein handbook reference) |
| 69640-38-6 |
| 2XEL |
| DTXSID90219907 |
| SCHEMBL12666317 |
| Q27461347 |
| MS-24988 |
| HY-115669 |
| CS-0104318 |
| AKOS040746213 |
Research Excerpts
Overview
Pentachloropseudilin (PClP) is a chlorinated phenylpyrrole compound. It was first isolated from Actinoplanes (ATCC33002) Its structure has been confirmed by chemical synthesis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pentachloropseudilin (PClP) is a reversible and allosteric inhibitor of type 1 myosin. " | ( Pentachloropseudilin Treatment Impairs Host Cell Invasion by Trypanosoma cruzi. Borges, BC; da Silva, CV; de Gouveia Santos, J; de Oliveira, RC; Marques, IT; Spirandelli da Costa, M; Teixeira, TL, 2022) | 3.61 |
| "Pentachloropseudilin (PClP) is a chlorinated phenylpyrrole compound that was first isolated from Actinoplanes (ATCC33002), and its structure has been confirmed by chemical synthesis. " | ( Pentachloropseudilin Inhibits Transforming Growth Factor-β (TGF-β) Activity by Accelerating Cell-Surface Type II TGF-β Receptor Turnover in Target Cells. Chen, CL; Chen, JJ; Chung, CL; Huang, YB; Kao, YC; Knölker, HJ; Lin, MH; Martin, R; Wang, SW; Wu, DC, 2018) | 3.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Myosin-2 Heavy Chain | Dictyostelium discoideum | IC50 (µMol) | 126.6000 | 126.6000 | 126.6000 | 126.6000 | AID977608 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1693700 | Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 4 hrs by neutral red uptake assay | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | In vitro and in vivo effects of inhibitors on actin and myosin. |
| AID1693705 | Antimigratory activity against human MDA-MB-231 cells assessed as cell migration by light microscopy | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | In vitro and in vivo effects of inhibitors on actin and myosin. |
| AID1693698 | Antimigratory activity against human MDA-MB-231 cells assessed as cell migration at 2.5 uM by light microscopy relative to control | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | In vitro and in vivo effects of inhibitors on actin and myosin. |
| AID600882 | Inhibition of Dictyostelium discoideum myosin 2 motor domain-activated ATPase activity by spectrophotometry based PK/LDH coupled ATPase assay | 2011 | Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11 | Inhibition of Myosin ATPase activity by halogenated pseudilins: a structure-activity study. |
| AID1693691 | Inhibition of rabbit skeletal muscle myosin-2 ATPase incubated for 20 mins followed by ATP addition and measured after 20 mins | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | In vitro and in vivo effects of inhibitors on actin and myosin. |
| AID1693699 | Antimigratory activity against human MDA-MB-231 cells assessed as minimum effective concentration by light microscopy | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | In vitro and in vivo effects of inhibitors on actin and myosin. |
| AID1693690 | Inhibition of rabbit muscle G-actin polymerization assessed as polymerized G-actin level at 25 uM incubated for 15 mins by spectrophotometric analysis (Rvb = 100 %) | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | In vitro and in vivo effects of inhibitors on actin and myosin. |
| AID600883 | Inhibition of Dictyostelium discoideum myosin 5b ATPase activity by spectrophotometric analysis | 2011 | Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11 | Inhibition of Myosin ATPase activity by halogenated pseudilins: a structure-activity study. |
| AID600881 | Inhibition of Dictyostelium discoideum myosin 1b ATPase activity by spectrophotometric analysis | 2011 | Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11 | Inhibition of Myosin ATPase activity by halogenated pseudilins: a structure-activity study. |
| AID1693704 | Cardiotoxicity in medaka embryo post hatching 24 hrs assessed as reduction in heart beat at 1.25 uM measured after 1 hr | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | In vitro and in vivo effects of inhibitors on actin and myosin. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2011 | The Journal of biological chemistry, Aug-26, Volume: 286, Issue:34 | Mechanism and specificity of pentachloropseudilin-mediated inhibition of myosin motor activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||